Plain-English translation of NCT06567743 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to treat high-risk, non-muscle-invasive bladder cancer. The medication is delivered directly into your bladder weekly for 6 weeks, and then on a maintenance schedule if needed. The study includes different groups depending on whether you've had prior bladder cancer treatment, and some participants will also receive a second medication called gemcitabine.
Currently, many patients with this type of bladder cancer either don't respond well to standard treatments like BCG therapy, or they face the risk of needing their bladder surgically removed. This trial is testing whether this new treatment can help preserve the bladder and control the cancer better.
You likely qualify if…
You likely don't qualify if…
You would receive weekly instillations (direct bladder infusions) of the medication for 6 weeks, followed by an evaluation at 3 months to check your progress. If needed, you may receive another 6-week course of treatment. After that, if your cancer hasn't returned, you'll move to a maintenance schedule with treatments every 3 months during the first year. The exact schedule depends on which group you're assigned to and how your cancer responds to treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States